top of page

Launch of the Cognitum Consortium

Updated: Oct 15, 2023

A fresh initiative in the realm of academic research, the Cognitum ARO Consortium, was officially launched on Sunday 27th August 2023 during the European Society of Cardiology Congress, Amsterdam.

This consortium, comprised of six world-class Academic Research Organizations (AROs), brings together global leaders in scientific and clinical excellence. The vision behind this initiative is to leverage the power of scientific and clinical excellence to create improved healthcare outcomes for our global community.

Welcome from Professor Neil Poulter - Founding Director


The Cognitum Consortium unites a prestigious group of AROs from across the globe, who are known for their commitment to excellence and positive global impact. The founding member institutes include the Centre for Chronic Disease Control in India, Einstein ARO in Brazil, Imperial Clinical Trials Unit (ICTU) - Global in the UK, RemediumOne in Sri Lanka, The George Institute in Australia and the Mayosi Research Group, University of Cape Town in South Africa.

Dr Patrícia Oliveira Guimarães presenting Einstein ARO


The Cognitum ARO Consortium has the capability to develop and manage all aspects of the clinical trial lifecycle, from study design, setup and trial delivery through to education and implementation. This is demonstrated through the previous successful completion by the Consortium partners of over 400 clinical trials. The consortium provides numerous additional benefits including:

  • in-house clinical expertise and academic/scientific excellence

  • the ability to produce high-impact publications

  • the capacity to shape clinical practice

  • the capability to identify and address implementation gaps.

These institutes are renowned for producing ground-breaking research that has pioneered real-world clinical impact.

Professor Prabhakaran presenting CCDC

Intended Impact

Through collaborative work and innovative approaches, the Cognitum ARO Consortium envisions accelerating the development of modern treatments and interventions that address the pressing challenges of noncommunicable and communicable diseases. As a result, it aspires to make significant contributions to reducing disease burden, improving patient care, and shaping the future of global healthcare.

Work With Us


bottom of page